Home Tags SGN-CD228A

Tag: SGN-CD228A

Medicus Pharma Secures Worldwide Rights to Pfizer’s Discontinued CD228-Directed ADC in...

Philadelphia-based Medicus Oncology gains global development and commercialization rights to PF-08046031 (CD228V), a melanotransferrin-targeted antibody-drug conjugate (ADC) originating from Pfizer's Seagen acquisition, as Pfizer retains a co-development role, milestone eligibility, and tiered royalties.